A preclinical study that performed a high-throughput screen of 3802 drugs has identified small molecules that inhibit epidermal growth factor receptor (EGFR) as top candidates for targeting FANCA-deficient HNSCC [85]. The gene discussed is FANCA; the disease is head and neck squamous cell carcinoma.